BRPI0409557A - proteìna inibidora recombinante de calicreìna, seqüência de dna, vetor de expressão, célula hospedeira, composição farmacêutica e seu uso, método de produção de proteìna inibidora recombinante de calicreìna e kit de diagnóstico para detecção de calicreìna - Google Patents
proteìna inibidora recombinante de calicreìna, seqüência de dna, vetor de expressão, célula hospedeira, composição farmacêutica e seu uso, método de produção de proteìna inibidora recombinante de calicreìna e kit de diagnóstico para detecção de calicreìnaInfo
- Publication number
- BRPI0409557A BRPI0409557A BRPI0409557-0A BRPI0409557A BRPI0409557A BR PI0409557 A BRPI0409557 A BR PI0409557A BR PI0409557 A BRPI0409557 A BR PI0409557A BR PI0409557 A BRPI0409557 A BR PI0409557A
- Authority
- BR
- Brazil
- Prior art keywords
- recombinant
- inhibitor protein
- expression vector
- dna sequence
- kallikrein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
"PROTEìNA INIBIDORA RECOMBINANTE DE CALICREìNA, SEQüêNCIA DE DNA, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, COMPOSIçãO FARMACêUTICA E SEU USO, MéTODO DE PRODUçãO DE PROTEìNA INIBIDORA RECOMBINANTE DE CALICREìNA E KIT DE DIAGNóSTICO PARA DETECçãO DE CALICREìNA". A presente invenção refere-se a uma proteína inibidora quimérica de uma protease que compreende uma seqüência polipeptídica inibidora e pelo menos uma seqüência polipeptídica de um local de interação entre enzima e substrato específico para protease. Outros objetos da presente invenção são o fornecimento de uma seqüência de DNA isolada e purificada que codifica a proteína inibidora quimérica de uma protease, um vetor de expressão caracterizado pelo fato de que compreende a mencionada seqüência de DNA isolada e purificada, uma célula hospedeira eucariótica ou procariótica transformada com este vetor de expressão e um método de produção de uma proteína inibidora quimérica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46034503P | 2003-04-04 | 2003-04-04 | |
| US60/460,345 | 2003-04-04 | ||
| PCT/IB2004/001040 WO2004087912A1 (en) | 2003-04-04 | 2004-04-05 | Inhibitor proteins of a protease and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0409557A true BRPI0409557A (pt) | 2006-04-18 |
| BRPI0409557B1 BRPI0409557B1 (pt) | 2019-07-23 |
| BRPI0409557B8 BRPI0409557B8 (pt) | 2021-05-25 |
Family
ID=33131923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0409557-0 BRPI0409557B8 (pt) | 2003-04-04 | 2004-04-05 | proteína recombinante inibidora de calicreína, sequência de dna, vetor de expressão, composição farmacêutica, uso da composição farmacêutica, método de produção da proteína recombinanete e kits de diagnóstico |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8975370B2 (pt) |
| EP (1) | EP1616007B1 (pt) |
| JP (1) | JP4754478B2 (pt) |
| KR (1) | KR101296367B1 (pt) |
| CN (1) | CN1798838B (pt) |
| AU (1) | AU2004225718B2 (pt) |
| BR (1) | BRPI0409557B8 (pt) |
| CA (1) | CA2521410C (pt) |
| CY (1) | CY1114526T1 (pt) |
| DK (1) | DK1616007T3 (pt) |
| ES (1) | ES2431548T3 (pt) |
| IL (1) | IL171158A (pt) |
| MX (1) | MXPA05010574A (pt) |
| NO (1) | NO334459B1 (pt) |
| PL (1) | PL1616007T3 (pt) |
| PT (1) | PT1616007E (pt) |
| SG (1) | SG161106A1 (pt) |
| SI (1) | SI1616007T1 (pt) |
| WO (1) | WO2004087912A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2163652B2 (en) | 2002-01-28 | 2023-05-31 | Life Technologies Corporation | Preparing crude biological extracts using protease, suitable for preparing cDNA |
| WO2006090282A2 (en) * | 2005-02-28 | 2006-08-31 | Universite De Lausanne | Recombinant inhibitor proteins of an hk14 protease and use thereof |
| US7964350B1 (en) | 2007-05-18 | 2011-06-21 | Applied Biosystems, Llc | Sample preparation for in situ nucleic acid analysis |
| AU2009207394B2 (en) * | 2008-01-21 | 2015-01-22 | Dermadis Sa | Use of serine protease inhibitors in the treatment of skin diseases |
| WO2010071833A1 (en) | 2008-12-19 | 2010-06-24 | Life Technologies Corporation | Proteinase k inhibitors, methods and compositions therefor |
| JP5667094B2 (ja) * | 2009-03-10 | 2015-02-12 | エムイーディー ディスカバリー エスエー | 好中球減少症の処置におけるセリンプロテアーゼ阻害剤の使用 |
| SG195083A1 (en) * | 2011-05-26 | 2013-12-30 | Baxter Int | Solid phase-bound elastase-binding assay for the measurement of alpha1,-antitrypsin activity |
| CN103044542B (zh) * | 2012-08-17 | 2015-08-19 | 常熟理工学院 | 鲫鱼卵中丝氨酸蛋白酶抑制剂及其基因和应用 |
| CN117169519B (zh) * | 2023-10-26 | 2024-01-30 | 艾康生物技术(杭州)有限公司 | 用于检测样本中tt3和/或tt4的解离剂和试剂盒 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| EP0462207B1 (en) | 1989-03-06 | 2001-02-07 | Board Of Regents, The University Of Texas System | T-pa mutants resistant to inhibition by their cognate inhibitors |
| US5612194A (en) * | 1989-06-23 | 1997-03-18 | Trustees Of The University Of Pennsylvania | Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors |
| US5827662A (en) * | 1989-06-23 | 1998-10-27 | The Trustees Of The University Of Pennsylvania | Methods for detecting genetic mutations resulting in protease inhibitor insufficiencies |
| US5723316A (en) * | 1989-06-23 | 1998-03-03 | Trustees Of The University Of Pennsylvania | α-1-antichymotrypsin analogues having chymase inhibiting activity |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| PT739355E (pt) | 1994-01-11 | 2005-01-31 | Dyax Corp | Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos |
| US6284873B1 (en) | 1999-03-12 | 2001-09-04 | Hybritech Incorporated | Complex of human kallikrein 2 (hK2) and protease inhibitor-6 (PI-6) in prostate tumor tissue and methods of using the complex |
-
2004
- 2004-04-05 ES ES04725742T patent/ES2431548T3/es not_active Expired - Lifetime
- 2004-04-05 KR KR1020057018938A patent/KR101296367B1/ko active IP Right Grant
- 2004-04-05 MX MXPA05010574A patent/MXPA05010574A/es active IP Right Grant
- 2004-04-05 WO PCT/IB2004/001040 patent/WO2004087912A1/en active Application Filing
- 2004-04-05 PT PT47257423T patent/PT1616007E/pt unknown
- 2004-04-05 PL PL04725742T patent/PL1616007T3/pl unknown
- 2004-04-05 DK DK04725742.3T patent/DK1616007T3/da active
- 2004-04-05 AU AU2004225718A patent/AU2004225718B2/en not_active Expired
- 2004-04-05 JP JP2006506440A patent/JP4754478B2/ja not_active Expired - Lifetime
- 2004-04-05 CN CN2004800152687A patent/CN1798838B/zh not_active Expired - Lifetime
- 2004-04-05 SG SG200718462-5A patent/SG161106A1/en unknown
- 2004-04-05 BR BRPI0409557-0 patent/BRPI0409557B8/pt active IP Right Grant
- 2004-04-05 EP EP04725742.3A patent/EP1616007B1/en not_active Expired - Lifetime
- 2004-04-05 CA CA2521410A patent/CA2521410C/en not_active Expired - Lifetime
- 2004-04-05 SI SI200432098T patent/SI1616007T1/sl unknown
- 2004-04-05 US US10/552,786 patent/US8975370B2/en active Active
-
2005
- 2005-09-28 IL IL171158A patent/IL171158A/en active IP Right Grant
- 2005-11-04 NO NO20055210A patent/NO334459B1/no unknown
-
2013
- 2013-10-23 CY CY20131100937T patent/CY1114526T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006523097A (ja) | 2006-10-12 |
| US8975370B2 (en) | 2015-03-10 |
| EP1616007B1 (en) | 2013-07-24 |
| AU2004225718A1 (en) | 2004-10-14 |
| PL1616007T3 (pl) | 2013-12-31 |
| CA2521410A1 (en) | 2004-10-14 |
| NO20055210D0 (no) | 2005-11-04 |
| WO2004087912A8 (en) | 2005-01-20 |
| WO2004087912A1 (en) | 2004-10-14 |
| BRPI0409557B8 (pt) | 2021-05-25 |
| JP4754478B2 (ja) | 2011-08-24 |
| KR20060010740A (ko) | 2006-02-02 |
| CY1114526T1 (el) | 2016-10-05 |
| CN1798838B (zh) | 2012-01-04 |
| SG161106A1 (en) | 2010-05-27 |
| BRPI0409557B1 (pt) | 2019-07-23 |
| MXPA05010574A (es) | 2006-03-09 |
| CA2521410C (en) | 2014-06-03 |
| DK1616007T3 (da) | 2013-10-28 |
| SI1616007T1 (sl) | 2013-12-31 |
| KR101296367B1 (ko) | 2013-08-14 |
| CN1798838A (zh) | 2006-07-05 |
| NO20055210L (no) | 2005-12-23 |
| IL171158A (en) | 2011-05-31 |
| PT1616007E (pt) | 2013-10-28 |
| ES2431548T3 (es) | 2013-11-26 |
| EP1616007A1 (en) | 2006-01-18 |
| AU2004225718B2 (en) | 2009-11-05 |
| NO334459B1 (no) | 2014-03-10 |
| US20060269536A1 (en) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053063A2 (es) | Proteina sustancialmente purificada y composicion farmaceutica que la comprende | |
| IL217489A (en) | U-pa polypeptides with specific substrate activity or activity and preparations and uses based on these polypeptides | |
| ATE406439T1 (de) | Eukaryontische signalsequenzen für polypeptid- expressions- und polypeptid- präsentationsbibliotheken | |
| FI961886A (fi) | Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit | |
| NO20043891L (no) | Anti-A-beta-antistoffer og deres anvendelse | |
| DK1673457T3 (da) | Nye svampeproteiner og nukleinsyrer, der koder for disse | |
| ATE227739T1 (de) | Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung | |
| NO20055210D0 (no) | Inhibitorproteiner av en protease og anvendelse derav | |
| AR047729A1 (es) | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) | |
| BRPI0507613A (pt) | expressão de plasminogênio e microplasminogênio em lentilha d'água | |
| NO20073808L (no) | BCMA polypeptider og anvendelser derav | |
| BR112018003594A2 (pt) | cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados | |
| ATE455792T1 (de) | Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon | |
| PE20021098A1 (es) | ANTICUERPOS ESPECIFICOS DE CD44v6 | |
| IL162568A0 (en) | fluorescent protein from aequorea coerulscens and uses thereof | |
| ATE412745T1 (de) | Antiangiogene peptide vom n-terminus von endostatin | |
| BRPI0413334A (pt) | vetores de multiantìgenos para melanoma | |
| Shibata et al. | Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide | |
| Helmerhorst | Whole saliva proteolysis: wealth of information for diagnostic exploitation | |
| Ritchie et al. | Characterization of crosslinking sites in fibrinogen for plasminogen activator inhibitor 2 (PAI‐2) | |
| WO2006090282A3 (en) | Recombinant inhibitor proteins of an hk14 protease and use thereof | |
| ATE466876T1 (de) | Immunogene konstrukte | |
| WO2003010184A3 (en) | A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis | |
| Kitano et al. | Cotiarinase is a novel prothrombin activator from the venom of Bothrops cotiara | |
| ATE213773T1 (de) | In apoptosis beteiligte cysteine protease cmh-1 und dns-sequenzen dafür |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 15/09 , C12N 15/15 , C12N 9/64 , C12P 21/02 Ipc: C12N 15/15 (2006.01), C12N 9/64 (2006.01), C12P 21 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/07/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |